Reported 1 day ago
Despite facing its worst year in history, Spanish pharmaceutical company Grifols SA remains a favored choice among analysts, with over two-thirds recommending a buy. The company has suffered a nearly 40% decline in shares due to concerns regarding its debt and corporate governance. Recent leadership changes and a significant debt raise aim to restore investor confidence, though challenges, including a high interest burden and short selling, persist. Most analysts predict a rebound, projecting an average stock price increase of over 60% in the next year.
Source: YAHOO